Cas9‐Cleavage Sequences in Size‐Reduced Plasmids Enhance Nonviral Genome Targeting of CARs in Primary Human T Cells

Ruirui Jing(First Affiliated Hospital Zhejiang University), Jie Sun(North Sichuan Medical University), Michel Sadelain(Columbia University Irving Medical Center), Yanting Duan, Xianhui Meng(Zhejiang University), Liling Qian(Center for Excellence in Brain Science and Intelligence Technology), Jiangqing Chen(First Affiliated Hospital Zhejiang University), Xun Zeng(First Affiliated Hospital Zhejiang University), Chun Zhou(Guangdong Pharmaceutical University), Kai Shang(Zhejiang University), Wei Chen(Second Affiliated Hospital of Zhejiang University), Junwei Liu(Hong Kong Polytechnic University), Tao Huang(Zhejiang University), Xiaoyan Wu(Union Hospital), Jin Jin(Zhejiang University), Peng Jiao(Zhejiang Chinese Medical University), Yanjie Huang(Westlake University), Weiwei Yin(Ministry of Education), Xiaofei Gao(Whitehead Institute for Biomedical Research)
Small Methods
May 19, 2021
10.1002/smtd.202100071
Cited by 33

Related Papers

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Gene therapy comes of age
|Science|2018|1.4k
Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch
|Cell|2017|1.1k
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
|Nature|2019|659
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
|Cancer Discovery|2021|551